Risk of breast cancer two years after a benign biopsy depends on the mammographic feature prompting recall
Por:
Tomas, MV, Louro, J, Roman, M, Saladie, F, Posso, M, Prieto, M, Vazquez, I, Bare, M, Penalva, L, Vidal, C, Bargallo, X, Sanchez, M, Ferrer, J, Espinas, JA, Quintana, MJ, Rodriguez-Arana, A, Castells, X
Publicada:
1 feb 2021
Resumen:
Objective: We aimed to explore whether the type of mammographic feature prompting a false-positive recall (FPR) during mammography screening influences the risk and timing of breast cancer diagnosis, particularly if assessed with invasive procedures.
Study design: We included information on women screened and recalled for further assessment in Spain between 1994 and 2015, with follow-up until 2017, categorizing FPRs by the assessment (noninvasive or invasive) and mammographic feature prompting the recall.
Main outcome measures: Breast cancer rates in the first two years after FPR (first period) and after two years (second period).
Results: The study included 99,825 women with FPRs. In both periods, the breast cancer rate was higher in the invasive assessment group than in the noninvasive group (first period 12 parts per thousand vs 1.9 parts per thousand, p < 0.001; second period 4.4 parts per thousand vs 3.1 parts per thousand, p < 0.001). During the first period, the invasive assessment group showed diverse breast cancer rates for each type of mammographic feature, with a higher rate for asymmetric density (31.9 parts per thousand). When the second period was compared with the first, the breast cancer rate decreased in the invasive assessment group (from 12 parts per thousand to 4.4 parts per thousand, p < 0.001) and increased in the noninvasive assessment group (from 1.9 parts per thousand to 3.1 parts per thousand, p < 0.001).
Conclusion: In the context of mammography screening, the risk of breast cancer diagnosis during the first two years after FPR was particularly high for women undergoing invasive assessment; importantly, the risk was modified by type of mammographic feature prompting the recall. This information could help to individualize follow-up after exclusion of malignancy.
Filiaciones:
Tomas, MV:
Inst Hosp Mar Investigac Med IMIM, Dr Aiguader 88, Barcelona 08003, Spain
Louro, J:
Inst Hosp Mar Investigac Med IMIM, Dr Aiguader 88, Barcelona 08003, Spain
Res Network Hlth Serv Chron Dis REDISSEC, Barcelona, Spain
Roman, M:
Inst Hosp Mar Investigac Med IMIM, Dr Aiguader 88, Barcelona 08003, Spain
Res Network Hlth Serv Chron Dis REDISSEC, Barcelona, Spain
Saladie, F:
Fundacio Lliga Invest & Prevencio Canc FUNCA, Avinguda Josep Laporte 2, Reus 43204, Spain
Posso, M:
Inst Hosp Mar Investigac Med IMIM, Dr Aiguader 88, Barcelona 08003, Spain
Res Network Hlth Serv Chron Dis REDISSEC, Barcelona, Spain
Prieto, M:
Gobierno Asturias, Consejeria Sanidad, Calle Ciriaco Miguel Vigil 9, Oviedo 33005, Spain
Vazquez, I:
Inst Hosp Mar Investigac Med IMIM, Dr Aiguader 88, Barcelona 08003, Spain
Bare, M:
Consorci Corporacio Sanitaria, Parc Tauli 1, Sabadell 08208, Spain
Penalva, L:
Hosp Gen Granollers, Av Francesc Ribas S-N, Granollers 08402, Spain
Vidal, C:
Inst Catala Oncol, Programa Prevencio & Control Canc, Gran Via LHosp 199-203, Lhospitalet De Llobregat 08908, Spain
Bargallo, X:
Hosp Clin Barcelona, Ctr Diagnost Imagen Clin CDIC, Calle Villarroel 170, Barcelona 08036, Spain
Sanchez, M:
Direcc Gen Salud Publ Gobierno Cantabria, C Federico Vial 13, Santander 39009, Spain
Ferrer, J:
Hosp Santa Caterina, Carrer Dr Castany S-N, Salt 17190, Girona, Spain
Espinas, JA:
Salut Generalitat Catalunya, Oncol Dept, Travessera Corts 131-159, Barcelona 08028, Spain
Quintana, MJ:
Hosp Santa Creu & Sant Pau, Dept Epidemiol, C San Antoni M Claret 167, Barcelona 08025, Spain
Rodriguez-Arana, A:
Inst Hosp Mar Investigac Med IMIM, Dr Aiguader 88, Barcelona 08003, Spain
Castells, X:
Inst Hosp Mar Investigac Med IMIM, Dr Aiguader 88, Barcelona 08003, Spain
Res Network Hlth Serv Chron Dis REDISSEC, Barcelona, Spain
|